Twin Capital Management Inc
Source: SEC Form 13F · as of Mar 2026Twin Capital Management Inc holds 19 biotech & pharma companies tracked by BioSniper, totaling $66.5M in value as of Mar 2026 (SEC Form 13F).
Companies held
19
Total value held
$66.5M
| Company | Shares | Value |
|---|---|---|
| LLYELI LILLY & Co | 15,229 | $14.0M |
| JNJJOHNSON & JOHNSON | 42,493 | $10.4M |
| AMGNAMGEN INC | 15,910 | $5.6M |
| MRKMerck & Co., Inc. | 39,931 | $4.8M |
| BMYBRISTOL MYERS SQUIBB CO | 78,220 | $4.7M |
| UNHUnitedHealth Group Incorporated Common Stock (DE) | 16,367 | $4.4M |
| ABBVAbbVie Inc. | 19,426 | $4.2M |
| ABTABBOTT LABORATORIES | 39,458 | $4.1M |
| GILDGILEAD SCIENCES, INC. | 27,595 | $3.8M |
| GMOptec International, Inc. | 37,433 | $2.8M |
| PFEPFIZER INC | 52,874 | $1.5M |
| CORCencora Inc. | 4,624 | $1.5M |
| REGNREGENERON PHARMACEUTICALS, INC. | 1,213 | $937K |
| INCYIncyte Corp. | 9,292 | $875K |
| VRTXVERTEX PHARMACEUTICALS INC / MA | 1,879 | $839K |
| BIIBBIOGEN INC. | 4,430 | $812K |
| HALOHALOZYME THERAPEUTICS, INC. | 11,422 | $738K |
| PMPhilip Morris International Inc | 1,411 | $233K |
| ELVElevance Health Inc. | 735 | $215K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.